Table 1.
Overview of the number of publications and postulated SNP associations per endpoint as reported and used for replication
| Reported endpoint | Reported patient (sub)group | No. publications | No. SNPs | No. genes | Endpoint and (sub)population used for replication | Study details + replication results |
| Recurrence | NMIBC | 14 | 21 | 16 | Recurrence in NMIBC | Table S1 |
| Recurrence | NMIBC+MIBC | 2 | 2 | 2 | ||
| Recurrence | TUR-only-/non-BCG-treated NMIBC | 5 | 14 | 10 | Recurrence in TUR-only-treated NMIBC | Table S2 |
| Recurrence | BCG-treated NMIBC | 27 | 37 | 32 | Recurrence in BCG-treateda NMIBC | Table S3 |
| Progression | NMIBC | 5 | 9 | 7 | Progression in NMIBC | Table S4 |
| Progression and/or cancer-specific survival | NMIBC+MIBC | 7 | 8 | 7 | Progression in NMIBC/ Overall survival in MIBC | Tables S4/S6 |
| Cancer-specific survival | Intravesical/systemic chemotherapy-treated NMIBC+MIBC | 1 | 6 | 2 | Progression in intravesical chemotherapy-treateda NMIBC (Reproducibility not evaluated in MIBC) | Table S5 |
| Progression | MIBC | 2 | 1 | 1 | Overall survival in MIBC | Table S6 |
| Cancer-specific survival | MIBC | 4 | 6 | 5 | ||
| Overall survival | MIBC | 3 | 14 | 9 | ||
| Overall survival | NMIBC+MIBC | 5 | 17 | 16 |
aTreated with at least six intravesical instillations. Please note: Numbers do not add up to the total of 114 evaluated SNPs, 83 genes, and 52 publications due to the existing overlap between the listed endpoints. Abbreviations: BCG: bacillus Calmette-Gurin; MIBC: muscle-invasive or metastatic bladder cancer; NMIBC: non-muscle-invasive bladder cancer; SNP: single nucleotide polymorphism; TUR: transurethral resection.